Lupin Entered into an Exclusive License and Supply Agreement with DKSH to Commercialize Five Biosimilar Candidates in the Philippines
Shots:
- The companies collaborated to commercialize five of Alvotech’s proposed biosimilars in the Philippines. Prolia, Xgeva, Simponi & Eylea are among the biosimilars planned under this agreement. Additionally, 2 suggested biosimilars for immunology and oncology are also included
- The agreement enhances Multicare’s oncology, rheumatology, gastroenterology, and ophthalmology, a portfolio that consists of 3 biosimilar candidates & ~50 generic therapies
- Lupin’s subsidiary Multicare will file for marketing approval and will be responsible for the distribution & commercialization of the biosimilars. The reference products are used to treat diseases related to ophthalmology, cancer, immunology, and bone disease
Ref: Lupin | Image: Lupin
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
